|Quantitative Cell-Based Bioassays for Individual and Combination Immune Checkpoint Immunotherapy Targets|
Zhi-jie Jey Cheng, Jamison Grailer, Pete Stecha, Jun Wang, Jim Hartnett, Frank Fan, and Mei Cong
Immune checkpoint receptors are promising new immunotherapy
targets for the treatment of a variety of diseases including cancer and
autoimmune-mediated disorders. We developed a suite of cell-based
bioluminescent reporter bioassays for individual and combination
immune checkpoint immunotherapy targets including: PD-1 (PD-L1 or PD-L2), CTLA-4, LAG-3, TIGIT, PD-1+TIGIT, GITR, 4-1BB, CD40, and OX40.
|A Novel Set of Serum-Free, Xeno-Free Differentiation Media for Adipogenesis, Osteogenesis and Chondrogenesis of Human Mesenchymal Stem Cells from Various Tissue Sources|
Mira Genser-Nir, Sharon Daniliuc, Marina Tevrovsky, Roni Hazan Brill, Yuliya-Yael Miropolski, David Fiorentini.
An overview of a novel SF, XF differentiation system which enables achieving defined conditions for rapid generation of differentiated hMSCs towards tissue engineering and drug screening applications
|A Synthetic CRISPR-Cas9 System for Homology-directed Repair|
John A. Schiel, Maren M. Gross, Emily M. Anderson*, Eldon T. Chou, Anja van Brabant Smith Dharmacon, part of GE Healthcare, 2650 Crescent Drive, Lafayette, CO 80026, USA
Synthetic, dual-RNA-encoded Cas9 is used for precise homology-directed repair (HDR) gene engineering. Both short and long (GFP) inserts are covered.
|Assessing Diversity in Cassava through the Application of Metabolomics|
Margit Drapala, Elisabete Carvalhoa, Laura Perez-Fonsa, Elliott Pricea, L. Augusto Becerra Lopez-Lavalleb, Paul D. Frasera
In the present study metabolomic platforms have been established for Cassava and used to assess the biodiversity present in Cassava germplasm collections and elucidate underlying biochemical mechanisms associated with traits of interest.
|Metabolomic profile of multiple sclerosis patients by means of 1H-NMR analysis|
Federica Murgia1, Lorena Lorefice 2 ,Eleonora Cocco2, Luigi Barberini2, Simone Poddighe1, Maria Rita Murru2, Raffaele Murru2, Jessica Frau2, MD Giuseppe Fenu2, MD, Giancarlo Coghe2, Francesco Del Carratore1, Luigi Atzori1, Maria Giovanna Marrosu3
Multiple sclerosis (MS) is a chronic disease characterized by a high level of heterogeneity. Metabolomics is an “-omics” approach with the potential to discover new biomarkers.
|Application of metabolomics in drug-resistant epilepsy research|
Federica Murgia1, Simone Poddighe1, Francesco Del Carratore1, Lorenzo Polizzi2, Antonella Muroni2, Luigi Barberini3, Monica Puligheddu3, Francesco Marrosu2 , Luigi Atzori1
Metabolomics represents an important tool for biomarker discovery in drug-resistant epilepsy and for the study of the pathophysiology of this disease.
|Changes in the metabolic profile of urine from mink during early pregnancy|
Mette Skou Hedemann
Metabolic profiling of urine from pregnant mink showed that ß-oxidation as well as protein metabolism is changed during pregnancy in mink and it is hypothesized that the changes occur to ensure optimal nutrition of the foetuses.
|A KNIME Pipeline for the Analysis of GC-MS Data in Metabolomics|
Sonia Liggi1, Maria Laura Santoru1, Cristina Piras1, Antonio Murgia2, Pierluigi Caboni2, Luigi Atzori1
A KNIME pipeline was developed to perform pre-processing of GC-MS data in an automated way and applied to a Inflammatory bowel diseases case study
|Metabolic response to everolimus in patient-derived xenografts of triple negative breast cancer|
Leslie R. Euceda1, Deborah K. Hill1,2, Endre Stokke1, Elisabetta Marangoni3, Tone F. Bathen1, Siver A. Moestue1,2
Everolimus treatment metabolic effects on TNBC PDX models were investigated using MR spectroscopy. PLS-DA successfully discriminated treated from controls and PDX expressing INPP4B and not. LMM revealed significant differences in 4/17 metabolites and two metabolite ratios between treated and controls.